Targeting MAOA to Improve Enzalutamide Responsiveness and Enhance Immunotherapy Through YAP1-Associated Signaling in Castration-Resistant Prostate Cancer

Castration-resistant prostate cancer (CRPC) represents a significant clinical challenge, characterized by resistance to androgen receptor antagonists such as enzalutamide (ENZ) and by immune tolerance mechanisms. Although monoamine oxidase A (MAOA) has been implicated in prostate cancer progression, its role in CRPC drug resistance and immune suppression remains underexplored. We investigated the role of MAOA in CRPC drug resistance and immune evasion using a series of in vitro and in vivo models, including ENZ-resistant cell lines, patient-derived organoid (PDO) models, patient-derived xenograft (PDX) models, and humanized mouse models. Our findings revealed that MAOA was significantly upregulated in ENZ-resistant CRPC models. Yes-associated protein 1 (YAP1) may link MAOA-associated drug resistance and immune evasion. In tumor cells, MAOA-associated YAP1 signaling is linked to alterations in reactive oxygen species (ROS) levels and NF-κB-related signaling, potentially contributing to ENZ resistance. Furthermore, MAOA-associated YAP1 signaling regulates tumor-cell PD-L1 expression and may contribute to immune evasion. In preclinical models, the combination of ENZ, MAOA inhibition, and PD-1 blockade exhibited enhanced antitumor efficacy compared with the other ENZ-containing treatment regimens. These findings suggest potential therapeutic benefits of targeting MAOA in CRPC. Combining MAOA inhibitors with ICIs could improve patient outcomes by addressing both intrinsic drug resistance and extrinsic immune evasion.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-13
DOI
https://doi.org/10.3390/ijms272210194
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting MAOA to Improve Enzalutamide Responsiveness and Enhance Immunotherapy Through YAP1-Associated Signaling in Castration-Resistant Prostate Cancer

Changhong Shi, 黄敏丽, Caiqin Zhang, Hanmu Chen et al.
2 links
International Journal of Molecular Sciences
Prostate Cancer Treatment and Research
article

Targeting MAOA to Improve Enzalutamide Responsiveness and Enhance Immunotherapy Through YAP1-Associated Signaling in Castration-Resistant Prostate Cancer

Changhong Shi, 黄敏丽, Caiqin Zhang, Hanmu Chen, Yaohua Hu, Yanzi Xing, Jumei Zhao, Mengyao Li, Yifan Ma
article en

Abstract

Castration-resistant prostate cancer (CRPC) represents a significant clinical challenge, characterized by resistance to androgen receptor antagonists such as enzalutamide (ENZ) and by immune tolerance mechanisms. Although monoamine oxidase A (MAOA) has been implicated in prostate cancer progression, its role in CRPC drug resistance and immune suppression remains underexplored. We investigated the role of MAOA in CRPC drug resistance and immune evasion using a series of in vitro and in vivo models, including ENZ-resistant cell lines, patient-derived organoid (PDO) models, patient-derived xenograft (PDX) models, and humanized mouse models. Our findings revealed that MAOA was significantly upregulated in ENZ-resistant CRPC models. Yes-associated protein 1 (YAP1) may link MAOA-associated drug resistance and immune evasion. In tumor cells, MAOA-associated YAP1 signaling is linked to alterations in reactive oxygen species (ROS) levels and NF-κB-related signaling, potentially contributing to ENZ resistance. Furthermore, MAOA-associated YAP1 signaling regulates tumor-cell PD-L1 expression and may contribute to immune evasion. In preclinical models, the combination of ENZ, MAOA inhibition, and PD-1 blockade exhibited enhanced antitumor efficacy compared with the other ENZ-containing treatment regimens. These findings suggest potential therapeutic benefits of targeting MAOA in CRPC. Combining MAOA inhibitors with ICIs could improve patient outcomes by addressing both intrinsic drug resistance and extrinsic immune evasion.

International Journal of Molecular SciencesVol. 27(22)
Guangzhou University of Chinese Medicine (CN), Yan'an University (CN), Air Force Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon